Cyclin dependent kinases in cancer: potential for therapeutic intervention. - Wikidata - wikimedia - TriplyDB

Cyclin dependent kinases in cancer: potential for therapeutic intervention.

Cyclin dependent kinases in cancer: potential for therapeutic intervention.

http://www.wikidata.org/entity/Q37987789

about

The emerging roles and therapeutic potential of cyclin-dependent kinase 11 (CDK11) in human cancer Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers DNA damage response genes and the development of cancer metastasis Amygdalin blocks bladder cancer cell growth in vitro by diminishing cyclin A and cdk2 Dual CDK4/CDK6 inhibition induces cell-cycle arrest and senescence in neuroblastoma.Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways.Requirement for CDK6 in MLL-rearranged acute myeloid leukemia.Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer.A Phase I study of cyclin-dependent kinase inhibitor, AT7519, in patients with advanced cancer: NCIC Clinical Trials Group IND 177.Cyclin-dependent kinase 11(p110) (CDK11(p110)) is crucial for human breast cancer cell proliferation and growth Wogonin inhibits the proliferation of myelodysplastic syndrome cells through the induction of cell cycle arrest and apoptosis.Association of RNF43 with cell cycle proteins involved in p53 pathway.Assembly, activation, and substrate specificity of cyclin D1/Cdk2 complexes.RNAi-mediated downregulation of DNA binding protein A inhibits tumorigenesis in colorectal cancer.Stimulation of the proliferation of human normal esophageal epithelial cells by fumonisin B1 and its mechanism.Crude extract and solvent fractions of Calystegia soldanella induce G1 and S phase arrest of the cell cycle in HepG2 cells.The state of the human proteome in 2012 as viewed through PeptideAtlas.Impact of EBV essential nuclear protein EBNA-3C on B-cell proliferation and apoptosis.The cyclin-dependent kinase family in the social amoebozoan Dictyostelium discoideum.MicroRNA-21 and multiple myeloma: small molecule and big function.Cyclin-dependent kinase inhibitors as marketed anticancer drugs: where are we now? A short survey.A Cyclin-Dependent Kinase Inhibitor, Dinaciclib, Impairs Homologous Recombination and Sensitizes Multiple Myeloma Cells to PARP Inhibition Morin Inhibits Proliferation, Migration, and Invasion of Bladder Cancer EJ Cells via Modulation of Signaling Pathways, Cell Cycle Regulators, and Transcription Factor-Mediated MMP-9 Expression.Fucoidan inhibits the proliferation of human urinary bladder cancer T24 cells by blocking cell cycle progression and inducing apoptosis.Lymphangioleiomyomatosis: New Treatment Perspectives.Inhibition mechanism of CDK-2 and GSK-3β by a sulfamoylphenyl derivative of indoline-a molecular dynamics study.Human CDK18 promotes replication stress signaling and genome stability.Cyclin-Dependent Kinase Inhibitors for the Treatment of Breast Cancer: Past, Present, and Future.Antiproliferative effect of alkaloids via cell cycle arrest from Pseuduvaria rugosa.Silencing of CDK2, but not CDK1, separates mitogenic from anti-apoptotic signaling, sensitizing p53 defective cells for synthetic lethality.Interactions of cyclin-dependent kinase inhibitors AT-7519, flavopiridol and SNS-032 with ABCB1, ABCG2 and ABCC1 transporters and their potential to overcome multidrug resistance in vitro.Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs.Tumor Protein p63/microRNA Network in Epithelial Cancer Cells.Modulation of G2/M cell cycle arrest and apoptosis by luteolin in human colon cancer cells and xenografts.6-(Methylsulfonyl) hexyl isothiocyanate as potential chemopreventive agent: molecular and cellular profile in leukaemia cell lines.Antitumor activities of Quercetin and Green Tea in xenografts of human leukemia HL60 cells.Prognostic significance of polo-like kinases in retinoblastoma: correlation with patient outcome, clinical and histopathological parameters.The Chinese herbs Scutellaria baicalensis and Fritillaria cirrhosa target NFκB to inhibit proliferation of ovarian and endometrial cancer cells.Clinical study of the novel cyclin-dependent kinase inhibitor dinaciclib in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia patients.Molecular principle of the cyclin-dependent kinase selectivity of 4-(thiazol-5-yl)-2-(phenylamino) pyrimidine-5-carbonitrile derivatives revealed by molecular modeling studies.

P2860

Q26751387-E45B3A83-F047-4428-AA17-B5227137839A Q28069910-D2EF4DCB-4A8C-4ADC-B913-55AE5397B6EF Q28388312-1ACC7FF2-5EA3-43AD-A912-0100C9CD0090 Q28542396-E01D3C3A-5D56-45B3-BB19-F3A17AA5FC6B Q30426051-49BCE0BC-D905-4C19-98FC-B5230324A8FB Q34147910-76B41385-64AD-4973-B391-812659D15988 Q34310186-0F6E6371-8CB5-43D4-9B5E-DE009638BAF7 Q34394399-A5E959D5-329E-4915-96E8-154D2CF12A7B Q34687067-23701055-6B85-4409-96E0-7BDD766E75A8 Q35626610-C45C8955-9CFC-4717-B894-68895B2A30EB Q36224965-9992CAFF-409E-4EF2-B8FF-10D340D57AAE Q36464762-AFE5A59D-F2BF-4885-B9AA-F41B6C5ED32D Q37185312-018CF77E-D587-4FB0-B291-065E20C05D9F Q37187537-C8056EA9-E3BB-4EF0-B7DE-3730758AD097 Q37387424-D7262867-676C-4B18-BEDE-F84413EC5481 Q37588090-90A748B7-8594-4443-B099-65C229A54FDD Q37591292-8923C632-8381-43DE-92AE-D3A15928D9B1 Q38086861-657A9177-9370-4183-B1B9-2ED1B066D5E3 Q38131284-EA63BBD9-271D-414E-8D59-17923BBFEA6E Q38224963-AA1713DE-8E66-4AE0-8C1C-87E189C3BBC8 Q38248633-7572D4D3-41FA-41E6-80CD-2B209EC4F93B Q38324762-00CF0924-02B6-4236-AA90-E88A7886C610 Q38405956-049C158C-53A8-4940-AFD4-B8C75239AE9A Q38438334-20059457-934A-438A-A1B3-BFD9063EA6E8 Q38484497-4F8B6BB7-4898-410B-9749-66C02E8F8E32 Q38670935-D9555642-E149-48D4-8025-8714EFF48302 Q38759647-5CCDF860-69ED-43A8-B2CD-17BB8237AA3F Q38810514-3E1FF86D-9870-46C6-9D05-4CB8B3D535BC Q39195103-DF7A3944-6BC6-460D-9DE5-5743FCAD4C86 Q39199216-83837D28-71F0-4EF6-9D42-520FA1D7BB59 Q40926668-84762193-576D-4E82-AA4D-AABE4BB53500 Q41963512-6DC4FD25-E97A-430A-B55F-20061C81FF8C Q42786047-E0FF1AE5-CC10-475E-9B3A-8E6B9DFCB324 Q49564125-F5F48E6F-209C-42FE-AA90-A76289266AB2 Q49707077-76A2BDBC-5879-42CF-9AD9-9FAB6CEE105A Q50145881-BB80E060-0331-4190-9C4A-52E79822A6A6 Q50580168-4F3C8E0B-3B2F-4256-8A45-0220FE6C1CF5 Q53082592-907CC42F-CCC0-406A-9D0E-0B02DCA17B0B Q54322737-8A63C893-7927-4F83-AD0C-48399FD0DD25 Q55033883-3D6134FA-710C-444A-9E6D-6C44313B7ACC

P2860

Cyclin dependent kinases in cancer: potential for therapeutic intervention.

http://www.wikidata.org/entity/Q37987789

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Cyclin dependent kinases in cancer: potential for therapeutic intervention.

@en

Cyclin dependent kinases in cancer: potential for therapeutic intervention.

@nl

type

label

Cyclin dependent kinases in cancer: potential for therapeutic intervention.

@en

Cyclin dependent kinases in cancer: potential for therapeutic intervention.

@nl

prefLabel

Cyclin dependent kinases in cancer: potential for therapeutic intervention.

@en

Cyclin dependent kinases in cancer: potential for therapeutic intervention.

@nl

P1433

Q37987789-9B913EC3-0F6C-4E7C-B986-05F12A972F11

P1476

Q37987789-CEB83675-F548-418A-82B5-E268E21B635F

P2093

Q37987789-58BB2E4F-822D-440F-8FF8-EB4E5123C607

Q37987789-D8C1BCB1-030E-4D61-A297-178A113ADD7D

Q37987789-DD8F10B8-6745-43D7-BF52-EF16E3F2E668

P2860

Q37987789-0012D29A-DA89-4FE5-B1F4-1C3AEDAC7436

Q37987789-029AC1EE-217A-4BB0-9E70-62826D43258D

Q37987789-096DE571-7CAE-46F6-A168-0C0AF382B648

Q37987789-0AAAA45E-A39D-4A2E-9A74-FFEB397C6197

Q37987789-0D6884A1-6A91-4A27-B1FE-42E7F7F3DA8C

Q37987789-0DFEB9AD-875E-432F-A877-61A6BED6B8B0

Q37987789-0EB764F9-A1D7-44E3-A001-859C9BB50ACF

Q37987789-12F67F85-7AC1-4D8B-98F0-01AB00593814

Q37987789-169A0BF0-2DDE-4DFE-8B25-C298E6BFFD2D

Q37987789-1821F9DA-3D84-4F64-A47E-C442E06E8BBA

P304

Q37987789-61AB661F-0DB5-4D13-88D3-ECEBDFA41976

P31

Q37987789-0190A31F-1E7E-4E51-A0EC-7F5BCE3A7510

P356

Q37987789-74954FA8-6AF2-45C2-9BAC-723EEBDEC2A8

P433

Q37987789-9F2BDAD8-5B27-4999-AD74-FC8E1BC42F6C

P478

Q37987789-8702EDBF-916E-47CC-9408-71C6F1EC81F5

P577

Q37987789-A274841E-3BE3-46AD-A70F-A1FDF369A32D

P5875

Q37987789-E2FA2030-2052-4F2D-94AF-871430777D62

P698

Q37987789-75B78D38-8709-4202-8C3C-422C0DF215F8

P356

P1433

Cancer Biology and Therapy

P1476

Cyclin dependent kinases in cancer: potential for therapeutic intervention.

@en

P2093

Loredana Santo

http://www.w3.org/2001/XMLSchema#string

Miriam Canavese

http://www.w3.org/2001/XMLSchema#string

Noopur Raje

http://www.w3.org/2001/XMLSchema#string

P2860

Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma

Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design

N-&-N, a new class of cell death-inducing kinase inhibitors derived from the purine roscovitine

TFIIH is negatively regulated by cdk8-containing mediator complexes

Cell cycle kinases as therapeutic targets for cancer

Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1

Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer

Cyclin-dependent kinase pathways as targets for cancer treatment

Cyclin E ablation in the mouse

The glamour and gloom of glycogen synthase kinase-3

P304

451-457

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/CBT.19589

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221858063

http://www.w3.org/2001/XMLSchema#string

P698

22361734

http://www.w3.org/2001/XMLSchema#string